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Purpose: To assess the safety and efficacy of one, two, or three trabecular microbypass stents 
in eyes with primary open-angle glaucoma (OAG) not controlled on ocular hypotensive medica-
tion. A total of 119 subjects were followed for 18 months postoperatively.
Materials and methods: Subjects with medicated intraocular pressure (IOP) 18–30 mmHg 
and postmedication-washout baseline IOP 22–38 mmHg were randomized to implantation of 
one, two, or three stents. Ocular hypotensive medication was to be used if postoperative IOP 
exceeded 18 mmHg.
Results: A total of 38 subjects were implanted with one stent, 41 subjects with two stents, and 
40 subjects with three stents. Both month 12 IOP reduction $20% without ocular hypoten-
sive medication vs baseline unmedicated IOP and month 12 unmedicated IOP #18 mmHg 
were achieved by 89.2%, 90.2%, and 92.1% of one-, two-, and three-stent eyes, respectively. 
Furthermore, 64.9%, 85.4%, and 92.1% of the three respective groups achieved unmedicated 
IOP #15 mmHg. Over the 18-month follow-up period, medication was required in seven 
one-stent subjects, four two-stent subjects, and three three-stent subjects. At 18 months, mean 
unmedicated IOP was 15.9±0.9 mmHg in one-stent subjects, 14.1±1.0 mmHg in two-stent 
subjects, and 12.2±1.1 mmHg in three-stent subjects. Month 18 IOP reduction was significantly 
greater (P,0.001) with implantation of each additional stent, with mean differences in reduc-
tion of 1.84 mmHg (95% confidence interval 0.96–2.73) for three-stent vs two-stent groups and 
1.73 mmHg (95% confidence interval 0.83–2.64) for two-stent vs one-stent groups. Adverse 
events through 18 months were limited to cataract progression with best-corrected visual acuity 
loss and subsequent cataract surgery.
Conclusion: In this series, implantation of each additional stent resulted in significantly greater 
IOP reduction with reduced medication use. Titratability of stents as a sole procedure was shown 
to be effective and safe, with sustained effect through 18 months postoperatively in OAG not 
controlled with medication.
Keywords: iStent, MIGS, OAG, intraocular pressure, IOP reduction, multiple stents
Introduction
Glaucoma, a degenerative progressive disease causing optic nerve damage to approxi-
mately 60 million people worldwide, causes bilateral blindness in approximately 
8.4 million.1 For many years preceding recent developments with microinvasive glau-
coma surgery (MIGS), the standard surgical modality has been trabeculectomy, along 
with the various postoperative sequelae of hypotony, progression of cataract, and bleb 
and choroidal complications, with concomitant visual loss.2 The development of ab 
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interno trabecular microbypass stents for use during MIGS 
has allowed patients with open-angle glaucoma (OAG) to 
experience significant reduction in both intraocular pressure 
(IOP) and medication usage, with lower risks and complica-
tions than with traditional incisional glaucoma surgery.3–7 
While initial work has shown the benefits of MIGS implan-
tation of one or multiple stents in conjunction with cataract 
surgery over the past 8 years, four recent prospective studies 
have focused on implantation of two trabecular microbypass 
stents as a stand-alone procedure – ie, in the absence of 
cataract surgery – with either presumptive administration 
of postoperative ocular hypotensive medication or with no 
postoperative medication.8–11 These two-stent sole-procedure 
studies have shown significant reductions in both IOP and 
medication use through 12 months.
The goal of the current study was to compare the effect 
of one, two, and three stents as a sole procedure on IOP 
and medication in subjects with OAG not controlled on 
two topical ocular hypotensive medications preoperatively. 
This report summarizes efficacy and safety data through 
18 months postoperatively.
Materials and methods
study design
The study design was a prospective, randomized, controlled 
trial of one, two, or three trabecular microbypass stents 
(iStent® Trabecular Micro-Bypass; Glaukos Corporation, 
Laguna Hills, CA, USA) in 120 eyes of 120 subjects enrolled 
at one clinical facility in Yerevan, Armenia. Ethical approval 
was obtained from the Armenian Ministry of Health. Study 
subjects signed an informed consent, and subject data-
collection methods were followed in accordance with the 
Declaration of Helsinki, revised in 2008. The clinical trial 
registration number is NCT01517477 (ClinicalTrials.gov).
Subjects were required to have OAG (pigmentary and 
pseudoexfoliative were allowed) not controlled on two 
preoperative medications, with preoperative medicated 
IOP $18 mmHg and #30 mmHg. The stage of glaucomatous 
optic neuropathy was to be mild to moderate, based on the 
structural and functional characteristics. The criteria used to 
diagnose glaucoma included the structural and functional 
deficits corresponding to typical glaucomatous abnormali-
ties, and elevated IOP (between 18 mmHg and 30 mmHg 
while on medication and .22 mmHg without medication). 
Additional inclusion criteria were cup:disk (C:D) ratio #0.9, 
normal angle anatomy, absence of peripheral anterior syn-
echia, rubeosis, or other angle abnormalities that could impair 
proper stent placement, and a willingness to attend scheduled 
follow-up examinations for 5 years postoperatively. Exclu-
sion criteria included pseudophakia with anterior-chamber 
intraocular lens, prior stent implantation in study eye, 
traumatic, uveitic, neovascular, or angle-closure glaucoma, 
glaucoma associated with vascular disorders, functionally 
significant visual field loss, prior incisional glaucoma sur-
gery, prior selective laser trabeculoplasty within 90 days of 
screening, prior argon laser trabeculoplasty, iridectomy, or 
laser iridotomy, visual field status at risk by washout period, 
unmedicated IOP expected to be .38 mmHg after washout 
period, active corneal inflammation or edema, clinically 
significant corneal dystrophy, corneal surgery of any type, 
corneal opacities, congenital or traumatic cataract, retinal or 
optic nerve disorders, elevated episcleral venous pressure, 
clinically significant sequelae from trauma, chronic ocular 
inflammatory disease, best-corrected visual acuity (BCVA) 
worse than 20/200, fellow eye in the trial, and pregnant or 
nursing women.
Subjects from the clinic population who met the screen-
ing criteria were instructed to undergo a 4-week washout for 
prostaglandin analogs, β-blockers, and combination medi-
cations, a 2-week washout for α-adrenergic agonists, and a 
5-day washout for carbonic anhydrase inhibitors. Subsequent 
to the medication-washout period, IOP was measured again at 
the baseline examination. At this second preoperative exami-
nation following medication washout, IOP was required to 
be $22 mmHg and #38 mmHg.
Subjects were to be randomized in a 1:1:1: ratio (40 sub-
jects per group) to either the one-stent, two-stent, or three-
stent group. Randomization treatment assignments were 
generated using a pseudorandom number generator. Surgeries 
were performed by one staff surgeon (LV) and five visiting 
surgeons (JML, CE, ACG, AMF, and LJK) at the clinical 
facility in Armenia. The evaluation schedule was postopera-
tive days 1 and 7 and months 1, 3, 6, 12, 18, 24, 30, 36, 42, 48, 
54, and 60. Postoperative ocular hypotensive medication was 
to be administered for elevated IOP (eg, IOP .18 mmHg). 
Subjects on postoperative medication were required to 
undergo annual postoperative medication-washout periods 
at months 12, 24, 48, and 60, then return 1 month later for 
clinical evaluation and reinstitution of medication if needed. 
Postoperative examinations were conducted by the staff 
surgeon and investigational site staff.
stent and surgical technique
The iStent is made of titanium, is heparin-coated, and is 
approximately 1.0 mm in length and 0.33 mm in height, 
with a snorkel bore diameter of 120 µm (Figure 1). The 
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iStent comes preloaded in a customized single-use stainless 
steel inserter used to guide and release the stent directly into 
Schlemm’s canal. The inserter features a release button acti-
vated by the surgeon to release the stent from the inserter.
Prior work by Samuelson et al has described the implan-
tation technique.6 Eyes were anesthetized using topical 
anesthesia. The surgeon advanced the inserter through a 
1.0 mm temporal clear corneal incision into the anterior 
chamber to approximately the pupillary margin. Under 
gonioprism visualization, the stent was gently guided 
through the trabecular meshwork and into Schlemm’s canal 
at the nasal position. Implantation of subsequent stents (for 
the two-stent and three-stent surgeries) was similar to this 
method, with subsequent stent placement 1–2 clock hours 
away from the previous stent. At the end of each surgical 
procedure, subjects were administered topical antibiotic 
medication (moxifloxacin) and corticosteroid medication 
(dexamethasone 0.1%). Subjects were prescribed the post-
operative antibiotic medication for 1 week and corticosteroid 
medication for 4 weeks, tapered from four times per day to 
once a day over the 4-week period.
Efficacy end points, safety, and data 
analyses
The primary efficacy end point of the study was month 12 
IOP reduction from baseline unmedicated IOP of $20%, 
without use of topical ocular medications at 12 months and 
without secondary glaucoma surgical procedures by the 
12-month visit. The secondary efficacy end point was month 
12 IOP #18 mmHg IOP, without use of topical ocular medica-
tions at 12 months and without secondary glaucoma surgical 
procedures by the 12-month visit. Additional efficacy measures 
included proportional analyses of month 12 IOP #15 mmHg, 
without use of topical ocular medications at 12 months and 
without secondary glaucoma surgical procedures by the 
12-month visit, mean IOP and medication usage through 
18 months postoperatively, and month 18 unmedicated mean 
IOP and change in IOP from preoperative values. Safety analy-
ses included assessment of BCVA, visual field via perimetry, 
slit-lamp evaluation, C:D ratio estimation, corneal thickness 
via pachymetry, complications, and ocular adverse events in 
all 119 eyes through 18 months postoperatively.
The intent-to-treat (ITT) population included all quali-
fied, randomized subjects who underwent stent-implantation 
surgery. Demographic and preoperative characteristics 
and safety analyses were summarized for the ITT popu-
lation. The modified ITT population included the subset 
of subjects who did not undergo cataract surgery prior to 
month 12. Proportional analyses of IOP reduction $20%, 
IOP #18 mmHg, and IOP #15 mmHg were performed on 
the modified ITT population. For these analyses, exact 95% 
confidence intervals (CIs) based on a binomial distribution 
were calculated for responder rates. Analyses of mean IOP 
at each postoperative exam were conducted on the number of 
available eyes at each exam that had not undergone secondary 
surgical interventions that might confound results. For these 
and other continuous variables, mean and standard deviation 
were provided. Tukey’s pairwise multiple-comparison test 
was performed to assess IOP reduction at month 18 between 
each of the two-stent and three-stent groups. For categori-
cal outcomes, counts and percentages were calculated. All 
statistical tests were performed using PC-SAS® software 
version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
subject disposition and demographics
A total of 251 subjects were screened for the study, and 152 
proceeded to medication washout and the baseline exam. Of 
the 152 subjects, 33 did not pass the baseline exam (IOP not 
in range after medication washout, or not did not complete 
medication washout). The remaining qualified subjects were 
randomized to implantation of one stent (n=38), two stents 
(n=41), or three stents (n=40). These subjects comprised 
the ITT population. Complete records through 18 months 
postoperatively are available for all 119 subjects.
All subjects were Caucasian. In the one-stent group, the 
mean (± standard deviation) age of the 27 men and eleven 
women was 68.1±9.1 years, and most eyes (n=23) were right 
eyes (Table 1). All eyes had a diagnosis of primary OAG. One 
eye in the one-stent group was pseudophakic, and the remain-
ing eyes were phakic. The mean visual field (mean deviation) 
was -4.72±4.42 dB, the mean C:D ratio was 0.68±0.11, and 
the mean corneal thickness was 528.4±34.3 µm. As per the 
inclusion criterion to qualify for the study, subjects were on 
two preoperative medications. Prior to the screening exam, 
Figure 1 The istent.
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a subset of subjects had discontinued medication use. At the 
time of the screening exam, the mean number of medications 
was 1.71±0.61. The average medicated IOP at this exam was 
19.8±1.3 mmHg, and mean baseline IOP after medication 
washout was 25.0±1.1 mmHg. Mean preoperative BCVA 
(logarithm of minimum angle of resolution) was 0.28±0.34. 
Demographic and preoperative characteristics for the two-
stent and three-stent groups were similar to those for the 
one-stent group (Table 1).
intraocular pressure and medication use
Both the primary and secondary efficacy end points were 
achieved by 89.2% of one-stent, 90.2% of two-stent, and 
92.1% of three-stent subjects (Table 2 and Figure 2). 
Month 12 IOP #15 mmHg without medication was achieved 
by 64.9% (n=24, 95% CI 47.5%–79.8%) of one-stent sub-
jects, 85.4% (n=35, 95% CI 70.8%–94.4%) of two-stent sub-
jects, and 92.1% (n=35, 95% CI 78.6%–98.3%) of three-stent 
subjects. Seven subjects in the one-stent group, four subjects 
in the two-stent group, and three subjects in the three-stent 
group required postoperative medication due to elevated 
IOP at visits ranging from month 1 to month 18 (Table 3). 
Thirteen of the 14 subjects were prescribed one medication, 
and one subject in the two-stent group was prescribed two 
medications.
Mean IOP over time and proportion of eyes on medication 
over time are shown in Table 4. Following a 1-month medica-
tion washout at month 12 for those eyes on medication, mean 
unmedicated IOP at months 12–13 was 14.9±1.9 mmHg, 
13.6±2.1 mmHg, and 12.7±2.1 mmHg in the three respec-
tive groups. IOP reduction was sustained in each of the 
groups throughout the 18-month postoperative period, with 
greater reduction in the multiple-stent groups vs the one-stent 
group. At 18 months, mean IOP was 15.6±1.5 mmHg in the 
one-stent group, 13.8±1.3 mmHg in the two-stent group, 
and 12.1±1.2 mmHg in the three-stent group. For eyes on 
no medication at month 18, IOP was 15.9±0.9 mmHg, 
14.1±1.0 mmHg, and 12.2±1.1 mmHg in the three respective 
groups, representing IOP decreases of 36.1%, 43.2%, and 
50.6% from baseline (Table 5). Each of the three pairwise 
comparisons of IOP reduction was significant (P,0.001), 
with mean differences in reduction of 3.58 mmHg (95% 
Table 1 Demographics and preoperative characteristics: iTT population
One-stent group (n=38) Two-stent group (n=41) Three-stent group (n=40)
age (years), mean ± sD; range 68.1±9.1; 49–83 67.8±9.3; 51–83 60.9±8.1; 49–85
sex, male/female 27/11 19/22 19/20
race, white/other 38/0 41/0 39/0
eye, OD/Os 23/15 21/20 17/23
glaucoma diagnosis, POag/PeX 38/0 40/1 39/0
lens status, phakic/pseudophakic 37/1 41/0 38/1
Visual field, MD (dB), mean ± sD -4.72±4.42 -5.20±5.65 -4.81±4.22 
C:D ratio, mean ± sD 0.68±0.11 0.71±0.14 0.70±0.12
Pachymetry (µm), mean ± sD 528.4±34.3 541.1±38.3 523.3±37.0
number of medications at screening,1 mean ± sD 1.71±0.61 1.76±0.54 1.51±0.69
Preoperative medicated iOP (mmhg), mean ± sD 19.8±1.3 20.1±1.6 20.4±1.8
Postwashout iOP (mmhg), mean ± sD 25.0±1.1 25.0±1.7 25.1±1.9
BCVa (logMar), mean ± sD 0.28±0.34 0.39±0.40 0.24±0.35
Notes: 1All subjects qualified for the study based on the use of two medications. Some subjects stopped medication use prior to the screening visit. The mean (SD) values 
for number of medications at screening reflect the medications subjects were taking at the time of the screening exam.
Abbreviations: iTT, intent-to-treat; sD, standard deviation; OD, oculus dexter (right eye); Os, oculus sinister (left eye); POag, primary open-angle glaucoma; 
PeX, pseudoexfoliative glaucoma; MD, mean deviation; C:D, cup:disk; iOP, intraocular pressure; BCVa, best-corrected visual acuity; Mar, minimum angle of resolution.
Table 2 Proportional analyses of month 12 IOP without medication: modified ITT population
Month 12 IOP One-stent group (n=37), n (%)
(95% CI)
Two-stent group (n=41), n (%)
(95% CI)
Three-stent group (n=38), n (%)
(95% CI)
iOP reduction $20% vs baseline iOP 33 (89.2%)
(74.6%–97.0%)
37 (90.2%)
(76.9%–97.3%)
35 (92.1%)
(78.6%–98.3%)
iOP #18 mmHg 33 (89.2%)
(74.6%–97.0%)
37 (90.2%)
(76.9%–97.3%)
35 (92.1%)
(78.6%–98.3%)
iOP #15 mmhg 24 (64.9%)
(47.5%–79.8%)
35 (85.4%)
(70.8%–94.4%)
35 (92.1%)
(78.6%–98.3%)
Abbreviations: IOP, intraocular pressure; ITT, intent-to-treat; CI, confidence interval.
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CI 2.66–4.49) for the three-stent vs one-stent groups, 
1.84 mmHg (95% CI 0.96–2.73) for the three-stent vs two-
stent groups, and 1.73 mmHg (95% CI 0.83–2.64) for the 
two-stent vs one-stent groups (Figure 3).
safety assessment
No intraoperative ocular adverse events occurred, including 
possible intraoperative adverse events, such as hyphema, iris 
damage, or corneal injury, or failure to implant stents. By 
month 18, four eyes (two each in the one-stent and three-
stent groups) underwent cataract surgery due to progression 
of cataract. In general, BCVA, C:D ratio, and visual field 
values did not appear to be different at 2 years postoperatively 
vs preoperative levels. No other adverse events or second-
ary glaucoma surgeries were reported. At 18 months, 79% 
of eyes in the one-stent group achieved BCVA of 20/40 or 
better vs 68% at the preoperative visit (Table 6). In each of 
the three groups, mean C:D ratio values at month 18 were 
the same as preoperative values. The mean visual field 
(mean deviation) values at 18 months of -4.9±4.71 dB (one 
stent), -5.96±5.84 dB (two stents), and -5.24±4.13 dB (three 
stents) were also generally similar to preoperative values.
Discussion
In the 15 years since trabecular bypass surgery was reported 
to be a viable method for aqueous outflow, laboratory and 
clinical research efforts have generated solid evidence to 
establish the safety and efficacy of MIGS with trabecular 
bypass stents up to 5 years postoperatively.3–15 Original clini-
cal work consisted of stent implantation in conjunction with 
cataract surgery with either one or multiple stents, while more 
recent work has involved stent surgery as a sole procedure.
The basis for incremental efficacy with use of multiple 
stents has been established previously in laboratory work.13–15 
Work by Hunter et al estimated reduction in IOP of 6 mmHg 
and reduction in total outflow resistance of 30% with a single 
stent, whereas IOP and outflow resistance reduced 8.9 mmHg 
and 44%, respectively, with the use of two stents.15 Similarly, 
Bahler et al estimated decreases of IOP of 6.1 mmHg with 
one iStent and 9.7 mmHg with two stents.13 This current clini-
cal study is consistent with the laboratory findings, in that a 
single stent lowered IOP by 36.1% and two stents afforded a 
43.2% reduction. Furthermore, the use of three stents resulted 
in IOP reduction of 50.6%. Therefore, the laboratory research 
is corroborated by this clinical report.
The findings with multiple-stent use in this current study 
are directionally consistent with earlier work by Belovay et al 
of two or three iStents during cataract surgery. They showed 
70% of patients achieving an IOP of #15 mmHg and 83% of 
subjects experiencing a reduction in hypotensive medication 
Figure 2 Proportional analyses of month 12 IOP without medication: modified ITT population.
Abbreviations: iOP, intraocular pressure; iTT, intent-to-treat.
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Table 3 Detail of subjects with postoperative medication added
Subject 
identification
Postoperative exam 
when medication1 added
IOP when 
medication added
One-stent group
8 Month 1 21 mmhg
63 Month 3 19 mmhg
80 Month 3 19 mmhg
5 Month 6 19 mmhg
10 Month 18 17.7 mmhg
51 Month 18 18.3 mmHg
101 Month 18 18 mmHg
Two-stent group
87 Month 31 20 mmhg
94 Month 6 19 mmhg
107 Month 6 18.7 mmHg
119 Month 6 19 mmhg
Three-stent group
92 Month 3 18 mmHg
71 Month 6 19 mmhg
74 Month 6 18.3 mmHg
Notes: 1Subject 87 was prescribed two medications at the end of the month 3 
exam. all other subjects were prescribed one medication.
Abbreviation: iOP, intraocular pressure.
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Table 4 Mean iOP (mmhg) and proportion of eyes on medications: available eyes at each exam1
Screening Baseline Month 1 Month 3 Month 6 Month 12 Months 12–132 Month 18
One-stent group
n 38 38 38 38 38 37 37 36
Mean iOP (sD) 19.8 (1.3) 25.0 (1.1) 12.2 (3.1) 12.8 (2.3) 13.1 (1.7) 14.4 (1.2) 14.9 (1.9) 15.6 (1.5)
On medication, n (%) 38 (100%) 0 (0%) 0 (0%) 1 (2.6%) 3 (7.9%) 4 (10.8%) 0 (0%) 4 (11.1%)
Two-stent group
n 41 41 41 41 41 41 41 41
Mean iOP (sD) 20.1 (1.6) 25.0 (1.7) 12.5 (2.7) 13.0 (2.1) 13.5 (2.3) 12.8 (1.4) 13.6 (2.1) 13.8 (1.3)
On medication, n (%) 41 (100%) 0 (0%) 0 (0%) 0 (0%) 1 (2.4%) 4 (9.8%) 0 (0%) 4 (9.8%)
Three-stent group
n 40 40 40 40 40 38 38 38
Mean iOP (sD) 20.4 (1.8) 25.1 (1.9) 12.0 (2.7) 12.8 (2.0) 12.9 (2.0) 12.2 (1.5) 12.7 (2.1) 12.1 (1.2)
On medication, n (%) 40 (100%) 0 (0%) 0 (0%) 0 (0%) 1 (2.5%) 3 (7.9%) 0 (0%) 3 (7.9%)
Notes: 1iOP and medication data at the start of the exam are reported. Data were included for subjects who had not undergone secondary surgical interventions that might 
confound results. 2eleven eyes were washed out of medication at month 12. Months 12–13 iOP = month 12 iOP for 105 eyes on no medication, and month 13 iOP for 
eleven eyes washed out of medication at month 12.
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
Table 5 Month 18 mean IOP and change in mean IOP vs screening and baseline exams: available eyes1 without medication
Mean IOP and change in mean IOP at month 18 One-stent group, n=32 Two-stent group, n=37 Three-stent group, n=35
Mean ± sD iOP for eyes without medication (mmhg) 15.93±0.90 14.07±1.00 12.24±1.12
Change (%) from screening medicated iOP (mmhg) -3.94 (-19.5) -5.99 (-29.5) -8.19 (-39.7)
Change (%) from baseline unmedicated iOP (mmhg) -9.04 (-36.1) -10.77 (-43.2) -12.61 (-50.6)
Note: 1Data were included for subjects who had not undergone secondary surgical interventions that might confound results.
Abbreviations: iOP, intraocular pressure; sD, standard deviation.
use at 1 year postoperatively.3 In our study, more than 80% 
of subjects were able to eliminate medication use. Moreover, 
in comparison to Belovay et al’s work and others that have 
shown the benefit of iStent implantation in conjunction with 
cataract surgery, our study evaluated the effects of stent 
implantation as a stand-alone procedure, thus allowing for 
evaluation of the effect of stent implantation on IOP reduc-
tion without the confounding effect of cataract surgery. 
Furthermore, while an earlier study by the MIGS study group 
of two stents plus one postoperative medication in patients 
with OAG not controlled on two preoperative medications 
showed month 12 IOP reduction $20% from baseline and 
month 12 IOP #18 mmHg with decrease of one medication 
in all patients,8 our study design evaluated outcomes after 
stent surgery without the use of postoperative medication.
To our knowledge, this prospective, randomized study to 
assess comparatively one, two, and three stents as the sole 
therapy in OAG eyes is the first ophthalmic medical device 
study to randomize subjects to receive single vs multiple 
surgical devices. While over 80% of subjects attained both 
the primary end point of month 12 IOP reduction without 
medication of $20% from baseline unmedicated IOP and the 
secondary end point of month 12 IOP #18 mmHg without 
medication, a greater percentage of multiple-stent subjects 
vs the single-stent group showed month 12 IOP #15 mmHg. 
Furthermore, with the use of each additional stent, mean IOP 
through 18 months was lower, and IOP reduction at month 18 
was significantly greater. Therefore, these data validate the 
increased circumferential flow within Schlemm’s canal via 
use of multiple stents vs one stent to achieve greater levels 
of IOP reduction.
Additional IOP reduction to levels lower than 15 mmHg is 
desirable in certain cases where target pressures are required 
in an attempt to retard disease progression. The National Eye 
Institute-sponsored AGIS study confirmed the association 
between low IOP and reduced progression of glaucomatous 
damage in advanced OAG patients.16 Our study showed that 
two stents can provide IOP decrease to less than 15 mmHg with 
minimal disruption to the ocular anatomy. For patients requir-
ing even lower IOP, surgeons can enhance the two-stent therapy 
with either an additional medication or an additional stent.
The safety data were very favorable, with no patients 
experiencing complications or adverse events commonly 
associated with conventional glaucoma procedures, such 
as endophthalmitis, bleb formation, hypotony, and fibro-
sis. Overall, BCVA, visual field measures, and C:D ratio 
did not appear different from preoperative values. With 
only one stent contained in each inserter, implantation of 
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Table 6 BCVa by visit: iTT population
Preoperative Month 1 Month 3 Month 6 Month 12 Month 18
One-stent group (n=38)
20/40 or better 26 (68%) 28 (74%) 29 (76%) 28 (74%) 29 (76%) 30 (79%)
20/100 or better 33 (87%) 33 (87%) 33 (87%) 33 (87%) 34 (89%) 34 (89%)
20/200 or better 38 (100%) 38 (100%) 38 (100%) 38 (100%) 38 (100%) 38 (100%)
Two-stent group (n=41)
20/40 or better 25 (61%) 27 (66%) 27 (66%) 27 (66%) 27 (66%) 27 (66%)
20/100 or better 31 (76%) 33 (80%) 33 (80%) 33 (80%) 33 (80%) 33 (80%)
20/200 or better 41 (100%) 41 (100%) 41 (100%) 41 (100%) 41 (100%) 41 (100%)
Three-stent group (n=40)
20/40 or better 29 (73%) 31 (78%) 31 (78%) 31 (78%) 32 (80%) 32 (80%)
20/100 or better 35 (88%) 35 (88%) 35 (88%) 35 (88%) 35 (88%) 35 (88%)
20/200 or better 40 (100%) 40 (100%) 40 (100%) 40 (100%) 40 (100%) 40 (100%)
Abbreviations: BCVa, best-corrected visual acuity; iTT, intent-to-treat.
multiple stents increased the number of insertion steps per 
eye. Despite the additional steps, safety data were similar 
across stent groups.
Limitations of this study include enrollment of a 
Caucasian population only, an open-label study design, a 
single-site study, and lack of masking to the study-treatment 
groups. The qualifying IOP at the baseline visit was not 
measured on multiple days, which may raise questions 
about regression to the mean. Furthermore, this study did 
not examine postural considerations of IOP measurements. 
It has been shown that IOP measurements are gener-
ally not affected in trabeculectomy-treated eyes, but that 
canaloplasty-treated eyes have higher IOP measured in a 
supine position than in a sitting position.17 Future studies 
may incorporate multiple centers with multiple measures 
of IOP, and could also examine the postural effect on IOP 
measurements. The cost of the implant was not factored 
into the study design, although this factor would be an 
important consideration in one’s practice. Finally, this report 
summarizes data through 18 months. A future report from 
this study could encompass longer postoperative follow-up 
through 5 years postoperatively. Still, the IOP reduction 
reported initially after surgery was shown to be sustained 
over the postoperative follow-up period.
In conclusion, this ongoing, prospective, randomized study 
showed sustained efficacy through 18 months after single or 
multiple iStents as the sole therapy in patients with OAG, 
with equivalent overall safety. Two stents offered significantly 
greater IOP reduction vs a single-stent implantation that was 
sustained through the postoperative follow-up, and three stents 
offered greater reduction vs two stents, thus demonstrating 
stent implantation as a titratable therapy that can be tailored 
for patients to achieve even lower target pressures depending 
on severity and/or progression of OAG. In doing so, the study 
validates the future role and promise of multistent injectable 
therapy in a preloaded device, such as the next-generation 
trabecular microbypass stents. Future reports will continue to 
evaluate long-term advantages of single vs multiple trabecular 
microbypass stents as viable therapy for OAG.
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Figure 3 Pairwise group comparisons of month 18 unmedicated IOP reduction.
Abbreviation: iOP, intraocular pressure.
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